<SEC-DOCUMENT>0001062822-23-000004.txt : 20230302
<SEC-HEADER>0001062822-23-000004.hdr.sgml : 20230302
<ACCEPTANCE-DATETIME>20230302160420
ACCESSION NUMBER:		0001062822-23-000004
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20230302
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230302
DATE AS OF CHANGE:		20230302

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30111
		FILM NUMBER:		23698803

	BUSINESS ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lxrx-20230302.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:fcabbf28-5aa0-465e-b7ab-43cfcb36f7d3,g:8ce1cd9d-e9d3-4ff7-b92c-e9a0b252862b,d:bfc6944df019445cb0d2f8f0d7462643--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lxrx-20230302</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M180L2ZyYWc6NjRlNzQ5NmEwZWI1NGMxOGE4YTgwNWMxMGIwYzdjZDMvdGFibGU6MTM0MDYxOGQ0YTI3NDcyMzhhMjIwY2FjMWRmZmVkMjkvdGFibGVyYW5nZToxMzQwNjE4ZDRhMjc0NzIzOGEyMjBjYWMxZGZmZWQyOV8wLTEtMS0xLTMzMTg3_2b2669ea-edac-4430-a280-a263580dd1e7">0001062822</ix:nonNumeric><ix:nonNumeric contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M180L2ZyYWc6NjRlNzQ5NmEwZWI1NGMxOGE4YTgwNWMxMGIwYzdjZDMvdGFibGU6MTM0MDYxOGQ0YTI3NDcyMzhhMjIwY2FjMWRmZmVkMjkvdGFibGVyYW5nZToxMzQwNjE4ZDRhMjc0NzIzOGEyMjBjYWMxZGZmZWQyOV8xLTEtMS0xLTMzMTg3_cb8c51a3-c903-495f-933d-c85d1c40ff0a">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lxrx-20230302.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ibfc6944df019445cb0d2f8f0d7462643_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF8xNjk2_b2cdb1cf-ce83-4573-aee7-3e0b27dc831c">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF8yNjU_304cf210-14fb-4055-ab87-f844fbb1d1ec">March 2, 2023</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF8xNjg5_f8d5f7d7-883d-43b9-8809-0a712904aea6">Lexicon Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.274%"><tr><td style="width:1.0%"></td><td style="width:32.755%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGFibGU6NTg3MTVkYzBhMzUyNDdhOTgyYTUxZmZkZmQwYjI4NjUvdGFibGVyYW5nZTo1ODcxNWRjMGEzNTI0N2E5ODJhNTFmZmRmZDBiMjg2NV8wLTAtMS0xLTMzMTg3_479ab992-f2ec-40b0-8a88-377c4c583140">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGFibGU6NTg3MTVkYzBhMzUyNDdhOTgyYTUxZmZkZmQwYjI4NjUvdGFibGVyYW5nZTo1ODcxNWRjMGEzNTI0N2E5ODJhNTFmZmRmZDBiMjg2NV8wLTEtMS0xLTMzMTg3_608c3547-be75-4c03-9434-5a0d7d6df624">000-30111</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGFibGU6NTg3MTVkYzBhMzUyNDdhOTgyYTUxZmZkZmQwYjI4NjUvdGFibGVyYW5nZTo1ODcxNWRjMGEzNTI0N2E5ODJhNTFmZmRmZDBiMjg2NV8wLTItMS0xLTMzMTg3_a3f827b2-6ce0-46c9-8e92-b0f99d9072cb">76-0474169</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF8xNjkw_6557aa4e-b55d-445e-b5af-d39b5ecd3f94">2445 Technology Forest Blvd., 11th Floor</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF8xNjk5_f5c66b0d-2213-4b7b-80fc-b471688deaae">The Woodlands</ix:nonNumeric>, <ix:nonNumeric contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF8xNzA1_2271f9f2-09e2-44bb-9b1b-b51a0d7b23b6">Texas</ix:nonNumeric> <ix:nonNumeric contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF80MTk_68f3e07b-c53a-404d-bc8d-69424f4f9c00">77381</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices and Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF80Nzg_4c9ffb53-e257-4bdb-8b9b-7376dd913551">281</ix:nonNumeric>) <ix:nonNumeric contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF8xNjkx_db38ff1b-a79c-420b-a23c-a090727b9103">863-3000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:34.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.372%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGFibGU6ODg3Mjk1NGM1ZDFmNDZkNTkyYTY1NWYyYjY0YjBmOTUvdGFibGVyYW5nZTo4ODcyOTU0YzVkMWY0NmQ1OTJhNjU1ZjJiNjRiMGY5NV8xLTAtMS0xLTMzMTg3_e97410c7-70ae-4493-babb-f319024245aa">Common Stock, par value $0.001</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGFibGU6ODg3Mjk1NGM1ZDFmNDZkNTkyYTY1NWYyYjY0YjBmOTUvdGFibGVyYW5nZTo4ODcyOTU0YzVkMWY0NmQ1OTJhNjU1ZjJiNjRiMGY5NV8xLTEtMS0xLTMzMTg3_9c04aa81-fe70-4959-a2e1-6943c961501e">LXRX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGFibGU6ODg3Mjk1NGM1ZDFmNDZkNTkyYTY1NWYyYjY0YjBmOTUvdGFibGVyYW5nZTo4ODcyOTU0YzVkMWY0NmQ1OTJhNjU1ZjJiNjRiMGY5NV8xLTItMS0xLTMzMTg3_5c247859-dd0b-435b-9299-7910af33cf81">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF8xNzAw_9ecfe74a-dad6-4064-889a-24fa4a4f7dd1">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17&#160;CFR&#160;230.425)</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF8xNzAx_e1dc2d08-9769-4abf-b499-0e6f3ad769ae">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17&#160;CFR 240.14a-12)</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF8xNzAy_1b6bd9e2-f856-4f98-91a5-540d077c967d">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17&#160;CFR 240.14d-2(b))</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF8xNjkz_9a13c1a9-b38b-4a57-b6c6-b3a7fb5693bb">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17&#160;CFR&#160;240.13e-4(c))</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div style="margin-bottom:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF8xNjk1_0d5d995f-871c-41e5-bb24-f739609b3487">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ibfc6944df019445cb0d2f8f0d7462643_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 2.02 &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Results of Operation and Financial Condition</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On March 2, 2023, we issu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ed a press release to report our financial results for the quarter ended December&#160;31, 2022.  A copy of the press release is attached to this current report on Form&#160;8-K as Exhibit&#160;99.1.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The information in this Form 8-K and the Exhibit attached to this Form 8-K shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ibfc6944df019445cb0d2f8f0d7462643_10"></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Exhibits </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:13.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressreleaseearnings03-02x.htm">Press Release of Lexicon Pharmaceuticals, Inc. dated </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressreleaseearnings03-02x.htm">March 2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressreleaseearnings03-02x.htm">, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressreleaseearnings03-02x.htm">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EX-104</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ibfc6944df019445cb0d2f8f0d7462643_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Signatures</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:52.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lexicon Pharmaceuticals, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date:   March 2, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">/s/ Brian T. Crum</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Brian T. Crum</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Senior Vice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">President and General Counsel</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pressreleaseearnings03-02x.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i89b5814fdce2404cb4487caeb9101c4d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER 2022</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">NDA for Sotagliflozin on Track for May 2023 PDUFA date following Late-Cycle Review Meeting</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">LX9211 Demonstrates Consistent Results in Full Data from RELIEF-DPN-1 in Diabetic Peripheral Neuropathic Pain and Top-Line Data from RELIEF-PHN-1 in Post-Herpetic Neuralgia</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Conference Call and Webcast at 5&#58;00 pm Eastern Time</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">The Woodlands, Texas, March 2, 2023</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> - Lexicon Pharmaceuticals, Inc. (Nasdaq&#58; LXRX), today reported financial results for the three months and full-year ended December 31, 2022 and provided an update on key corporate milestones.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;We are on track for the PDUFA action date in May of this year for our NDA for sotagliflozin for the treatment of heart failure, as confirmed during this week&#8217;s FDA late-cycle review meeting,&#8221; said Lonnel Coats, Lexicon&#8217;s chief executive officer.  &#8220;We believe the uniqueness of our data from the SOLOIST-WHF trial provides a point of clinical differentiation and provides a strong opportunity to launch into a growing market with recently adopted medical treatment guidelines recommending the use of SGLT inhibitors as a key pillar of heart failure treatment.&#8221;  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;We continue to advance the science across our portfolio with the upcoming presentation of sotagliflozin-related analyses at the American College of Cardiology&#8217;s 72nd Annual Scientific Session Together With World Heart Federation&#8217;s World Congress of Cardiology in New Orleans, Louisiana, including a featured presentation on the time to clinical benefit of sotagliflozin in people with worsening heart failure. In parallel, we are equally excited about the clinical progress of our AAK1-inhibitor, LX9211.  We plan to advance LX9211 into late-stage development in neuropathic pain, supported by data from Phase 2 proof-of-concept studies in painful diabetic neuropathy (PDN) and postherpetic neuralgia (PHN), both completed in 2022.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">Fourth Quarter Highlights</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Sotagliflozin</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">On November 6, a new analysis of results from the SOLOIST-WHF Phase 3 outcomes study of sotagliflozin was presented at the American Heart Association Scientific Sessions 2022 in Chicago, Illinois. The oral presentation was titled </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#8220;The effect of the dual SGLT1 and 2 inhibitor sotagliflozin on cardiovascular mortality and hospital readmission rates for heart failure at 30- and 90-days post discharge in patients with type 2 diabetes hospitalized for worsening heart failure in the SOLOIST-WHF trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; and showed that treatment with sotagliflozin resulted in a significant relative risk reduction versus placebo of approximately 50% for readmission for non-fatal heart failure events and for the composite of cardiovascular death and readmission for heart failure at both 30 and 90 days following hospital discharge.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">A poster was presented at the American Society of Nephrology Kidney Week 2022 annual scientific meeting in Orlando, Florida on November 5. The poster was titled </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#8220;Effect of sotagliflozin on albuminuria in patients with type 2 diabetes and chronic kidney disease&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> and described the results of a post hoc analysis of clinical data from the SCORED trial that showed sotagliflozin significantly reduced urine albumin-to-creatinine ratio (UACR) and had favorable effects on albuminuria progression and regression from a higher UACR category.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">LX9211</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">An oral presentation, titled &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of LX9211 in the Treatment of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN-1),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">was given at the 16th Annual Pain Therapeutics Summit in Washington, D.C.  on November 14. The presentation of full data from the entire 11-week evaluation period of the study, which included a 5-week placebo run-off period following the initial 6-week treatment period, showed consistent and statistically significant treatment-period benefits in measures of particular importance in diabetic peripheral neuropathic pain for both dose arms compared to placebo, such as reductions in burning pain (p&#60;0.001 and p&#61;0.017, respectively) and interference of pain on sleep (p&#61;0.005 and p&#61;0.002, respectively).</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">On December 21, we announced topline results of our RELIEF-PHN-1 Phase 2 proof-of-concept study of LX9211 in postherpetic neuralgia. LX9211 achieved a reduction in average daily pain score (ADPS) of 2.42 points from baseline at week 6 compared to a reduction of 1.62 points in the placebo arm, with a placebo adjusted difference of 0.80 points (p&#61;0.12).  Although these results did not reach statistical significance on the primary endpoint of the study, overall study results demonstrated clear evidence of effect.  Separation of LX9211 from placebo on ADPS was seen at week 1 and maintained consistently thereafter, with an average placebo-adjusted reduction over the 6-week dosing period of 0.80 points (p&#61;0.03).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">Fourth Quarter 2022 Financial Highlights</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Unless otherwise stated, all comparisons are for the fourth quarter and full year of 2022 compared to the fourth quarter and full year of 2021. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Research and Development (R&#38;D) Expenses&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Research and development expenses for the fourth quarter of 2022 decreased to $14.0 million from $16.5 million for the corresponding period in 2021, and for the full-year </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">decreased to $52.8 million from $55.0 million in 2021, primarily due to lower professional and consulting fees in 2022 related to the preparations for the submission of our application for regulatory approval to market sotagliflozin for heart failure. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Selling, General and Administrative (SG&#38;A) Expenses&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Selling, general and administrative expenses for the fourth quarter of 2022 increased to $16.3 million from $8.8 million for the corresponding period in 2021, and for the full-year increased to $48.1 million from $32.3 million in 2021, primarily due to increases in salaries and benefits, professional and consulting costs and marketing costs relating to preparations for the commercial launch of sotagliflozin in heart failure. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Net Loss&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Net loss for the fourth quarter of 2022 was $30.5 million, or $0.16 per share, as compared to a net loss of $25.6 million, or $0.17 per share, in the corresponding period in 2021. For the fourth quarters of 2022 and 2021, net loss included non-cash, stock-based compensation expense of $3.3 million and $2.2 million, respectively. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Net loss for the full-year 2022 was $101.9 million, or $0.62 per share, as compared to a net loss of $87.8 million, or $0.60 per share in 2021. For the full years of 2022 and 2021, net loss included non-cash, stock-based compensation expense of $11.5 million and $10.6 million, respectively. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Cash and Investments&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> As of December 31, 2022, Lexicon had $138.4 million in cash and investments, as compared to $86.7 million as of December 31, 2021.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">Conference Call and Webcast Information</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Lexicon management will hold a live conference call and webcast today at 5&#58;00 pm ET &#47; 4&#58;00 pm CT to review its financial and operating results and to provide a general business update.  The dial-in number for the conference call is 888-886-7786 and the conference ID for all callers is 70766912. The live webcast and replay may be accessed by visiting Lexicon&#8217;s website at  www.lexpharma.com&#47;events. An archived version of the webcast will be available on the website for 14 days. </font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About Lexicon Pharmaceuticals</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients&#8217; lives. Through its Genome5000&#8482; program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, diabetes and metabolism and other indications.  For additional information, please visit www.lexpharma.com.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Safe Harbor Statement</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">This press release contains &#8220;forward-looking statements,&#8221; including statements relating to Lexicon&#8217;s financial position and long-term outlook on its business, including the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of sotagliflozin, LX9211 and its other potential drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon&#8217;s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management&#8217;s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon&#8217;s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of sotagliflozin, LX9211 and its other potential drug candidates on its anticipated timelines, successfully commercialize any products for which it obtains regulatory approval, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon&#8217;s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under &#8220;Risk Factors&#8221; in Lexicon&#8217;s annual report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i89b5814fdce2404cb4487caeb9101c4d_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Lexicon Pharmaceuticals, Inc.</font></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Selected Financial Data</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Operations Data</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands, except per share data)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and other revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development, including stock-based compensation of $1,184, $676, $4,253 and $4,284, respectively</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,977&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,498&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,816&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,046&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative, including stock-based compensation of $2,084, $1,552, $7,267 and $6,293, respectively</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,329&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,846&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,083&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,342&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Total operating expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,306&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,344&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,899&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,388&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,278)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,330)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,760)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,090)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,103)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,780)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(802)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,596&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,494)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,611)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,944)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,758)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share, basic and diluted</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.62)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.60)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net loss per common </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;share, basic and diluted</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,726&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,897&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,733&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,652&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;As of </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Balance Sheet Data</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;December 31, 2021 </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash and investments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,357&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,743&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Property and equipment, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;1,176 </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Goodwill</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,543&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;44,543 </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,299&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;136,909 </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Long-term debt, net of issuance costs</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,579&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;-   </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Accumulated deficit</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,589,720)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;(1,487,776)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total stockholders' equity</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,124&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;113,595 </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i89b5814fdce2404cb4487caeb9101c4d_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">For Investor Inquiries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Carrie Siragusa</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Lexicon Pharmaceuticals, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">csiragusa&#64;lexpharma.com</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">For Media Inquiries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Alina Kolomeyer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Lexicon Pharmaceuticals, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">akolomeyer&#64;lexpharma.com</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>lxrx-20230302.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:fcabbf28-5aa0-465e-b7ab-43cfcb36f7d3,g:8ce1cd9d-e9d3-4ff7-b92c-e9a0b252862b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://lexpharma.com/20230302" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://lexpharma.com/20230302">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20230302_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20230302_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://lexpharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>lxrx-20230302_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:fcabbf28-5aa0-465e-b7ab-43cfcb36f7d3,g:8ce1cd9d-e9d3-4ff7-b92c-e9a0b252862b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_66a1fb8b-f344-4030-a8ca-ee0c6f859504_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6e4b6d1a-ca06-4055-a18e-4021b3b581b3_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e11a8d75-056f-436f-9290-c53154aa8fb5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_706dcf6d-b2f9-41f7-ac58-7d170a4d8181_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a9c7036e-9938-47ca-a4d5-9745e8e4d211_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_9b85a989-6dee-4826-89b0-1d29e0d39d8d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_d638fdaf-788f-4e26-b817-799e08118937_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b14d6b7a-439f-4e61-9f29-53a6d1fd7fd0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_92d4ab4e-8e0a-4d45-9973-159fa6821362_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5d07abed-9a01-4a2d-b26d-4087d16008c3_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0634e98e-5275-4ec3-b4f7-59604e1ed3de_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_54c9e272-a625-4220-b45a-d32f8d7a340e_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_901ce7f7-7a8b-4ba6-bbe9-ec93f22f8cfd_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7ba56b06-0930-436c-b18c-3414afaa922b_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_92a98a2f-0726-493d-b722-ebbaa0a15def_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_ea03be2f-5617-4157-b60d-3822aab0f3c7_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_369ae472-bed2-4e95-8a91-d2cf995c2d1e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_0e825be8-9bdd-45cf-ad4d-5557626ad9be_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7b865705-9bc2-46cd-958b-0c0b2b305189_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_126682f8-cdd0-40f5-b1a0-a1001e18beae_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_bb751e0e-25ba-49f9-b954-e37894ceacdf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_bac2b026-7657-4e71-bb49-e71ecf9c7560_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>lxrx-20230302_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:fcabbf28-5aa0-465e-b7ab-43cfcb36f7d3,g:8ce1cd9d-e9d3-4ff7-b92c-e9a0b252862b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://lexpharma.com/role/Cover" xlink:type="simple" xlink:href="lxrx-20230302.xsd#Cover"/>
  <link:presentationLink xlink:role="http://lexpharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_649b483c-81d0-4516-b7b9-0725fb97bfb6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_dab58fb6-5f8c-46d0-a3d7-f70da4ac7a2d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649b483c-81d0-4516-b7b9-0725fb97bfb6" xlink:to="loc_dei_DocumentType_dab58fb6-5f8c-46d0-a3d7-f70da4ac7a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f9d01346-7e18-4fe6-b43b-c8067fee9ce8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649b483c-81d0-4516-b7b9-0725fb97bfb6" xlink:to="loc_dei_EntityTaxIdentificationNumber_f9d01346-7e18-4fe6-b43b-c8067fee9ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b3e304c2-572b-4cfe-92c6-f30e4032e857" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649b483c-81d0-4516-b7b9-0725fb97bfb6" xlink:to="loc_dei_EntityRegistrantName_b3e304c2-572b-4cfe-92c6-f30e4032e857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_dceafcc1-45fc-4b14-afdd-e2ef28c40c04" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649b483c-81d0-4516-b7b9-0725fb97bfb6" xlink:to="loc_dei_EntityFileNumber_dceafcc1-45fc-4b14-afdd-e2ef28c40c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_99a8b966-8836-479c-8ee6-aa5b2d8227d0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649b483c-81d0-4516-b7b9-0725fb97bfb6" xlink:to="loc_dei_EntityIncorporationStateCountryCode_99a8b966-8836-479c-8ee6-aa5b2d8227d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_cd244adc-f797-45fd-8500-9eb814ddc58a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649b483c-81d0-4516-b7b9-0725fb97bfb6" xlink:to="loc_dei_EntityAddressAddressLine1_cd244adc-f797-45fd-8500-9eb814ddc58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ede3a893-f4df-4540-86e5-34aa16d1b23b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649b483c-81d0-4516-b7b9-0725fb97bfb6" xlink:to="loc_dei_EntityAddressCityOrTown_ede3a893-f4df-4540-86e5-34aa16d1b23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_33e3e38b-be8b-4e89-ba3b-cf45da5d6856" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649b483c-81d0-4516-b7b9-0725fb97bfb6" xlink:to="loc_dei_EntityAddressStateOrProvince_33e3e38b-be8b-4e89-ba3b-cf45da5d6856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_54ee5c82-7276-4d9d-a98b-84fb50c7c1da" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649b483c-81d0-4516-b7b9-0725fb97bfb6" xlink:to="loc_dei_EntityAddressPostalZipCode_54ee5c82-7276-4d9d-a98b-84fb50c7c1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_6f059af9-3bd0-4ccb-bee5-1c9420aecd52" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649b483c-81d0-4516-b7b9-0725fb97bfb6" xlink:to="loc_dei_CityAreaCode_6f059af9-3bd0-4ccb-bee5-1c9420aecd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_0eb22dac-b913-41aa-bbd5-4329556e6bc2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649b483c-81d0-4516-b7b9-0725fb97bfb6" xlink:to="loc_dei_LocalPhoneNumber_0eb22dac-b913-41aa-bbd5-4329556e6bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4a288102-1d2e-46ba-a382-147d93ed72a4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649b483c-81d0-4516-b7b9-0725fb97bfb6" xlink:to="loc_dei_Security12bTitle_4a288102-1d2e-46ba-a382-147d93ed72a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_bdcb6293-059f-4529-a2ff-0a393e4b5fe8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649b483c-81d0-4516-b7b9-0725fb97bfb6" xlink:to="loc_dei_TradingSymbol_bdcb6293-059f-4529-a2ff-0a393e4b5fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3f1d74c0-4950-4187-80c7-c3baf42a787e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649b483c-81d0-4516-b7b9-0725fb97bfb6" xlink:to="loc_dei_SecurityExchangeName_3f1d74c0-4950-4187-80c7-c3baf42a787e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_aae20270-f988-4634-a00f-a7742510d4e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649b483c-81d0-4516-b7b9-0725fb97bfb6" xlink:to="loc_dei_WrittenCommunications_aae20270-f988-4634-a00f-a7742510d4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_fb84d73d-0436-49cb-999b-a84ac5e3b751" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649b483c-81d0-4516-b7b9-0725fb97bfb6" xlink:to="loc_dei_SolicitingMaterial_fb84d73d-0436-49cb-999b-a84ac5e3b751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ead1349d-ea36-4239-9382-babfaf723d62" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649b483c-81d0-4516-b7b9-0725fb97bfb6" xlink:to="loc_dei_DocumentPeriodEndDate_ead1349d-ea36-4239-9382-babfaf723d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_98c2e1b1-c977-4d34-97ca-295d2c7840fd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649b483c-81d0-4516-b7b9-0725fb97bfb6" xlink:to="loc_dei_AmendmentFlag_98c2e1b1-c977-4d34-97ca-295d2c7840fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_bbbffe3b-af92-437b-9c7a-b8fb05736883" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649b483c-81d0-4516-b7b9-0725fb97bfb6" xlink:to="loc_dei_EntityCentralIndexKey_bbbffe3b-af92-437b-9c7a-b8fb05736883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_1bfbb7f5-502a-48fc-874b-04869f8739a1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649b483c-81d0-4516-b7b9-0725fb97bfb6" xlink:to="loc_dei_PreCommencementTenderOffer_1bfbb7f5-502a-48fc-874b-04869f8739a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_8a24fd34-49ed-4c24-a711-d94c972a5580" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649b483c-81d0-4516-b7b9-0725fb97bfb6" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_8a24fd34-49ed-4c24-a711-d94c972a5580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f5f2fdc1-af40-475a-9c0f-ae4e47dba139" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649b483c-81d0-4516-b7b9-0725fb97bfb6" xlink:to="loc_dei_EntityEmergingGrowthCompany_f5f2fdc1-af40-475a-9c0f-ae4e47dba139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139982546610432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0474169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lexicon Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2445 Technology Forest Blvd., 11th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">The Woodlands<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">863-3000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LXRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar.  02,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001062822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>lxrx-20230302_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lxrx-20230302.xsd" xlink:type="simple"/>
    <context id="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M180L2ZyYWc6NjRlNzQ5NmEwZWI1NGMxOGE4YTgwNWMxMGIwYzdjZDMvdGFibGU6MTM0MDYxOGQ0YTI3NDcyMzhhMjIwY2FjMWRmZmVkMjkvdGFibGVyYW5nZToxMzQwNjE4ZDRhMjc0NzIzOGEyMjBjYWMxZGZmZWQyOV8wLTEtMS0xLTMzMTg3_2b2669ea-edac-4430-a280-a263580dd1e7">0001062822</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M180L2ZyYWc6NjRlNzQ5NmEwZWI1NGMxOGE4YTgwNWMxMGIwYzdjZDMvdGFibGU6MTM0MDYxOGQ0YTI3NDcyMzhhMjIwY2FjMWRmZmVkMjkvdGFibGVyYW5nZToxMzQwNjE4ZDRhMjc0NzIzOGEyMjBjYWMxZGZmZWQyOV8xLTEtMS0xLTMzMTg3_cb8c51a3-c903-495f-933d-c85d1c40ff0a">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF8xNjk2_b2cdb1cf-ce83-4573-aee7-3e0b27dc831c">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF8yNjU_304cf210-14fb-4055-ab87-f844fbb1d1ec">2023-03-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF8xNjg5_f8d5f7d7-883d-43b9-8809-0a712904aea6">Lexicon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGFibGU6NTg3MTVkYzBhMzUyNDdhOTgyYTUxZmZkZmQwYjI4NjUvdGFibGVyYW5nZTo1ODcxNWRjMGEzNTI0N2E5ODJhNTFmZmRmZDBiMjg2NV8wLTAtMS0xLTMzMTg3_479ab992-f2ec-40b0-8a88-377c4c583140">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGFibGU6NTg3MTVkYzBhMzUyNDdhOTgyYTUxZmZkZmQwYjI4NjUvdGFibGVyYW5nZTo1ODcxNWRjMGEzNTI0N2E5ODJhNTFmZmRmZDBiMjg2NV8wLTEtMS0xLTMzMTg3_608c3547-be75-4c03-9434-5a0d7d6df624">000-30111</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGFibGU6NTg3MTVkYzBhMzUyNDdhOTgyYTUxZmZkZmQwYjI4NjUvdGFibGVyYW5nZTo1ODcxNWRjMGEzNTI0N2E5ODJhNTFmZmRmZDBiMjg2NV8wLTItMS0xLTMzMTg3_a3f827b2-6ce0-46c9-8e92-b0f99d9072cb">76-0474169</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF8xNjkw_6557aa4e-b55d-445e-b5af-d39b5ecd3f94">2445 Technology Forest Blvd., 11th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF8xNjk5_f5c66b0d-2213-4b7b-80fc-b471688deaae">The Woodlands</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF8xNzA1_2271f9f2-09e2-44bb-9b1b-b51a0d7b23b6">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF80MTk_68f3e07b-c53a-404d-bc8d-69424f4f9c00">77381</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF80Nzg_4c9ffb53-e257-4bdb-8b9b-7376dd913551">281</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF8xNjkx_db38ff1b-a79c-420b-a23c-a090727b9103">863-3000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGFibGU6ODg3Mjk1NGM1ZDFmNDZkNTkyYTY1NWYyYjY0YjBmOTUvdGFibGVyYW5nZTo4ODcyOTU0YzVkMWY0NmQ1OTJhNjU1ZjJiNjRiMGY5NV8xLTAtMS0xLTMzMTg3_e97410c7-70ae-4493-babb-f319024245aa">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGFibGU6ODg3Mjk1NGM1ZDFmNDZkNTkyYTY1NWYyYjY0YjBmOTUvdGFibGVyYW5nZTo4ODcyOTU0YzVkMWY0NmQ1OTJhNjU1ZjJiNjRiMGY5NV8xLTEtMS0xLTMzMTg3_9c04aa81-fe70-4959-a2e1-6943c961501e">LXRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGFibGU6ODg3Mjk1NGM1ZDFmNDZkNTkyYTY1NWYyYjY0YjBmOTUvdGFibGVyYW5nZTo4ODcyOTU0YzVkMWY0NmQ1OTJhNjU1ZjJiNjRiMGY5NV8xLTItMS0xLTMzMTg3_5c247859-dd0b-435b-9299-7910af33cf81">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications
      contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF8xNzAw_9ecfe74a-dad6-4064-889a-24fa4a4f7dd1">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF8xNzAx_e1dc2d08-9769-4abf-b499-0e6f3ad769ae">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF8xNzAy_1b6bd9e2-f856-4f98-91a5-540d077c967d">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF8xNjkz_9a13c1a9-b38b-4a57-b6c6-b3a7fb5693bb">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJmYzY5NDRkZjAxOTQ0NWNiMGQyZjhmMGQ3NDYyNjQzL3NlYzpiZmM2OTQ0ZGYwMTk0NDVjYjBkMmY4ZjBkNzQ2MjY0M18xL2ZyYWc6NWUwNWRjNTIwZWE1NDAwOTgzYzY1YzA5YWQ3OTIwNTQvdGV4dHJlZ2lvbjo1ZTA1ZGM1MjBlYTU0MDA5ODNjNjVjMDlhZDc5MjA1NF8xNjk1_0d5d995f-871c-41e5-bb24-f739609b3487">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M2ZZ33=1ND2"P,;E+E-((?.!7GNE_"G_J6I#9A=K*6B_%Y18Q)R]*10F3D<$
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M/[&\UDX:?^:+X3]>?P%02P$"% ,4    " ")@&)6!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( (F
M8E:#&C^A[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( (F 8E:97)PC$ 8  )PG   3              "
M <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ B8!B5L07(U:!
M!   )1$  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( (F 8E:?H!OPL0(  .(,   -              "
M <0,  !X;"]S='EL97,N>&UL4$L! A0#%     @ B8!B5I>*NQS     $P(
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9>&UL4$L%!@     )  D /@(  !@4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="lxrx-20230302.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lexpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="lxrx-20230302.htm">lxrx-20230302.htm</File>
    <File>lxrx-20230302.xsd</File>
    <File>lxrx-20230302_lab.xml</File>
    <File>lxrx-20230302_pre.xml</File>
    <File>pressreleaseearnings03-02x.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lxrx-20230302.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "lxrx-20230302.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lxrx-20230302_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lxrx-20230302_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lxrx-20230302.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "lxrx",
   "nsuri": "http://lexpharma.com/20230302",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230302.htm",
      "contextRef": "i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://lexpharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20230302.htm",
      "contextRef": "i0fbfcd73bfa346ac9476fa98deae5412_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001062822-23-000004-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001062822-23-000004-xbrl.zip
M4$L#!!0    ( (F 8E:>'4*0_Q,  -)_   1    ;'AR>"TR,#(S,#,P,BYH
M=&WM/5M7XLBZ[_M7U&'.F6VO94'EGM#=[F4+NIT1[$:Z'7AQ55(5"(:$28*
MO_Y\50$5D18OB/;8#RU)ZO;=;Y7*I_^,^R&ZX$D:Q-'G@E(D!?2?G4__@_%?
M7QI'J!)[PSZ/,K27<)IQAD9!UD6GC*?GR$_B/CJ-D_/@@F(L^^S%@TD2=+H9
M4HFJW7J8E'V/NJZOVMB@E&#=-#AV+>IB7?-\S]5,WV+:=J=L>USQF,,P=YB&
M==^WL.NH'EQ2XJJ&:INJN\W*KN^9CJXSGRCPQ_!<PE3?]@FS=%,U=4U,V\T
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M6P%F>V^\@86&8H+=]I!^:G^5+ NZ2'K(&P>[+7!JVE&@G&TRZ;GVN>ZXIFM
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MO'&6WV9E\7"62S6E6 :,!PH0!;7B9:"OL6GL Q32A$4$(S_"=F+?.]Y(A=_
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MA=B'DR-KT98.NTW/EKC=MCRWG0VWX=D21F.[L\W&7I[KY]0O]:E3BADE#"<
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M B[#X\'3PCLG4H4X'> >=Z>>-J0Z6$=G=M[] 78TS!K=US-K$)HHPF& :N5
M3#,6&K]C9(E*G8-9B("OP1P&S9X'9''I"3=8.QQII;OYG#%<YO0A =1$7L$2
MX@G*:.YTTIKG.:#50ELA<'@!<E!:.5Q,WA#ZY)&G+N W-]'!QZ6(5*+0%CMB
M*)'E/ 2+>>U-@2]@ZUOF_Q+IRBS#WP,9P+J1F?.D!&.-_*"P, U0T#9*Y<7D
M:2T(B N+F=#5BP]8D@:RLPTSE0A&$E%DNG+9RN5C.8+\H;6Y%[)O8/Q&&.^3
MR@*&WXZT T!8$1- GXAP$FF_^ _/#2 \^@Z1:I9$(&=<%2B<AJ@H[> ^@V
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MU;TX?%H8X[1[#,,UO0\@[3V2ODASB4%>> C :<,62 ,&).S3D(CY>>P_PYU
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M_]/_ U!+ 0(4 Q0    ( (F 8E:>'4*0_Q,  -)_   1              "
M 0    !L>')X+3(P,C,P,S R+FAT;5!+ 0(4 Q0    ( (F 8E80=5KS:0(
M &4'   1              "  2X4  !L>')X+3(P,C,P,S R+GAS9%!+ 0(4
M Q0    ( (F 8E9+.J#B0@H  !A=   5              "  <86  !L>')X
M+3(P,C,P,S R7VQA8BYX;6Q02P$"% ,4    " ")@&)6!VXJ[ZD&  #6,
M%0              @ $[(0  ;'AR>"TR,#(S,#,P,E]P<F4N>&UL4$L! A0#
M%     @ B8!B5N3PB(($&P  I_0  !X              ( !%R@  '!R97-S
M<F5L96%S965A<FYI;F=S,#,M,#)X+FAT;5!+!08     !0 % % !  !70P
"   !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
